• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Materials Research >Sorafenib delivered by cancer cell membrane remodels tumor microenvironment to enhances the immunotherapy of mitoxantrone in breast cancer
【24h】

Sorafenib delivered by cancer cell membrane remodels tumor microenvironment to enhances the immunotherapy of mitoxantrone in breast cancer

机译：Sorafenib通过癌细胞膜递送肿瘤微环境，增强乳腺癌中丝兰癌的免疫疗法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The negative regulation effect of tumor microenvironment (TME) greatly compromised the efficacy of various cancer treatments, especially cancer immunotherapy. As a result, it is generally recognized that remodeling of TME along with the treatment is a promising way to realize satisfactory cancer therapy. Here, in our study, a drug delivery system (DDS) composed cancer cell membrane (CCM) vehicle loaded mitoxantrone (Mit) and sorafenib (Sfn) was proposed with the aim to combine TME regulation and chemotherapy-induced immunotherapy in one platform. Our results confirmed that after treating with this DDS, the Mit induced immunogenic cell death (ICD) could be augmented by Sfn-based TME regulation to realize effective cancer immunotherapy. The Sfn was shown to downregulate of the regulatory T cells (Treg) level while activating the effector T cells of TME. The synergetic TME regulation along with cancer immunotherapy might be a promising way for advanced cancer treatment.
机译：肿瘤微环境（TME）的负调节效应大大损害了各种癌症治疗，尤其是癌症免疫疗法的疗效。结果，通常认识到，TME随着治疗的重塑是实现令人满意的癌症治疗的有希望的方式。在此，在我们的研究中，提出了一种药物递送系统（DDS）组合的癌细胞膜（CCM）载体负载的米萨兰酮（MIT）和Sorafenib（SFN），其目的是将TME调控和化疗诱导的免疫疗法结合在一个平台上。我们的结果证实，在用这种DDS治疗后，MIT诱导的免疫原性细胞死亡（ICD）可以通过基于SFN的TME调节来增强，以实现有效的癌症免疫疗法。在激活TME的效应T细胞的同时，SFN显示在调节T细胞（Treg）水平的下调。协同作用TME调节以及癌症免疫疗法可能是一种有前途的晚期癌症治疗方法。

著录项

  • 来源
    《Journal of Materials Research》 |2020年第24期|3296-3303|共8页
  • 作者

    Jing Chen; Jian Huang;

  • 作者单位

    Department of Breast Surgery The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang Province 310009 PR China Department of Radiation Oncology Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou Zhejiang Province 310022 PR China;

    Department of Breast Surgery The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou Zhejiang Province 310009 PR China Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province Hangzhou Zhejiang Province 310009 PR China;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号